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ABSTRACT
Background and Objectives: Statin therapy after percutaneous coronary intervention (PCI) has been associated with re-
duced major adverse cardiovascular events (MACE). However, it has been less clear as to whether statin therapy before acute 
coronary syndrome (ACS) is beneficial. We studied the effect of previous statin therapy, initiated ≥1 month before PCI, on 
the outcome of patients with ACS who had undergone early invasive strategies. Subjects and Methods: We stratified 479 
consecutive patients with ACS who had undergone PCI, according to preprocedural statin administration as follows: previ-
ous statin-treated patients (statin group, n=237) and statin-naive patients (control group, n=242). The incidence of periproce-
dural myocardial infarction (MI) and in-hospital MACE was assessed. Results: The incidence of Braunwald class III angina 
and MI presentation were significantly lower in the statin group than in the control group. Angiographic and procedural 
characteristics were similar between the two groups; however, slow/no reflow phenomenon occurred more frequently in the 
control group. After PCI, the incidence of periprocedural MI was higher in the control group than in the statin group (6.6% vs. 
2.1%, p=0.016). Multivariate analysis revealed that no prior use of statin {odds ratio (OR)=2.8; 95% confidence interval (CI)= 
1.1-7.2; p=0.038), procedural complication (OR=4.0; 95% CI=1.5-10.5; p=0.004), stent overlap (OR=4.7; 95% CI=1.3-16.4; 
p=0.015), and old age (OR=3.2; 95% CI=1.2-8.0; p=0.016) were independent predictors for in-hospital MACE. Conclu-
sion: Previous statin therapy before ACS was associated with milder clinical presentation and lower incidence of in-hospital 
MACE after early invasive strategies. The beneficial outcome is attributable to a significant reduction in periprocedural MI 
after PCI. (Korean Circ J 2011;41:458-463)
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Introduction
Statins have been known to significantly reduce cardiovas-
cular clinical events in a variety of patients, ranging from th-
ose with established cardiovascular disease to those who are 
at risk for cardiovascular disease.
1-6) The role of statins in pa-
tients with acute coronary syndrome (ACS) also has been cl-
arified. Large scaled randomized trials have shown that early 
and high doses of statin therapy significantly improve the 
prognosis in patients with ACS.
7)8)
Since an early invasive strategy has been the standard ther-
apy for ACS, several studies have been conducted to deter-
mine whether periprocedural use of statins is beneficial in 
these cases. Some reports have suggested that statin loading 
prior to percutaneous coronary intervention (PCI) is associ-
ated with reduced mortality and decreased periprocedural 
myocardial injury after PCI in patients with ACS.
9)10) Another 
study demonstrated that pretreatment with statin for three 
to seven days in patients with ACS was associated with a re-
duction of myocardial necrosis and late cardiac events after 
PCI.
11)12) However, it has been less clear as to whether statin Kyeong Ho Yun, et al.   459
therapy before a coronary event is beneficial.
Therefore, we designed a retrospective study involving con-
secutive ACS patients who underwent PCI. We compared the 
hospital course and mortality between those patients who had 
undergone previous statin treatment for more than one mon-
th, which was set to avoid statin therapy after the occurrence 
of ACS and to enroll patients showing the lipid lowering effect 
of statin, as well as patients without statin pretreatment.
 
 Subjects and Methods
Study population
We analyzed a single center ACS and PCI cohort from De-
cember 2008 to December 2009. During the study period, 479 
consecutive patients were recruited and followed-up during 
their clinical course to document patient characteristics, acu-
te therapy, PCI data, and hospital outcome. According to the 
patient’s past medication history, we divided the patients into 
two groups, and compared their hospital course. Two hundr-
ed thirty-seven patients had previously undergone statin tr-
eatment for more than one month prior to PCI (statin group) 
and 242 patients were statin-naive patients (control group). 
All patients gave informed consent for processing their an-
onymous data according to a protocol approved by the Insti-
tutional Review Board of Wonkwang University Hospital.
Percutaneous coronary intervention
PCI was performed according to the current clinical prac-
tice at the physician’s discretion and within 48 hours after ad-
mission. In all patients, aspirin (300 mg/day) and clopidogrel 
(300 mg/day) were loaded before the procedure. An intrave-
nous bolus of 5,000 U of unfractionated heparin was given, 
and then additional heparin was given to maintain an activat-
ed clotting time greater than 300 s during the procedure. Pl-
atelet glycoprotein IIb/IIIa inhibitors (GPI) were administer-
ed according to operator preference.
Post-procedural management
Aspirin (100 mg/day), clopidogrel (75 mg/day) and statins 
were prescribed to all patients following the procedure. Cre-
atine kinase MB fraction (CK-MB) and troponin T were mea-
sured before (at admission, mean 18±4 hours before PCI), 
and at 8, 16, and 24 hours after PCI. High-sensitivity C-reac-
tive protein (hsCRP) and fibrinogen were also assessed be-
fore PCI and at 24 hours after PCI.
Definitions
Periprocedural myocardial infarction (MI) was defined as 
a postprocedural increase of CK-MB more than three times 
higher than the normal upper limit in patients with a normal 
baseline level of enzyme. In patients with elevated baseline 
levels of CK-MB, MI was defined as a subsequent increase of 
more than 3-fold in CK-MB from baseline values.
13) Non-
periprocedural MI was defined as spontaneous MI occurr-
ing for more than 24 hours after PCI. Further, MACE includ-
ed a composite of death, periprocedural, and non-periproce-
dural non-fatal MI, ischemic stroke, and target vessel revas-
cularization.
Statistical analysis
All measurements were represented as means±standard 
deviation or absolute numbers (percentage). The inter-group 
analysis was done by independent t-test and χ2 test, using St-
atistical Package for the Social Sciences (SPSS) 12.0 for Win-
dows (SPSS Inc., Chicago, IL, USA). To compare changes in 
cardiac and inflammatory biomarkers before and after PCI, 
we used a paired t-test. A multivariable logistic regression 
model was constructed to predict in-hospital MACE. The fol-
lowing variables, selected according to significance in a uni-
variate analysis, were inserted into the logistic regression an-
alysis: no prior use of statin, procedural complication, age 
more than 65 years, thrombus lesion, stent overlap, MI present-
ation on admission, and use of glycoprotein IIb/IIIa receptor 
antagonist. Statistical significance was set at p<0.05.
Results
Baseline characteristics
The baseline clinical characteristics of patients in the con-
trol and statin groups have been provided in Table 1. In the 
statin group, 63.5% of patients received atorvastatin, 12.9% 
rosuvastatin, 11.4% ezetimibe/simvastatin, 5.2% simvastatin, 
3.0% pravastatin, 2.5% pitavastatin, and 1.5% fluvastatin. The 
duration of statin therapy was as follows; 22.1% of the pa-
tients, more than 1 year; 53.5%, 6 months to 1 year; and 24.4%, 
1 to 6 months. Further, the statin group had lower baseline low 
density lipoprotein (LDL) cholesterol levels (124±40 mg/dL 
vs. 113±42 mg/dL, p=0.002) and incidences of Braunwald cl-
ass III angina and MI presentation were also significantly lo-
wer in the statin group than in the control group. 
Coronary angiography and revascularization
Most patients (97%) received drug-eluting stents, and over 
30% of the patients received multi-vessel stenting (Table 2). 
Angiographic and procedural characteristics were similar be-
tween the two groups; however, slow/no reflow phenomenon 
was more frequent in the control group (7% vs. 3%, p=0.014).
Changes of cardiac biomarker and inflammatory 
marker
The statin group revealed lower baseline serum troponin 
T and fibrinogen levels (Table 3) and less elevation of both 
markers after PCI. Mean baseline hsCRP levels were similar 
between the two groups; however, after PCI, the peak value 460   Previous Statin Therapy in ACS and PCI
of hsCRP were elevated significantly higher in the control gr-
oup. That is, hsCRP increased from 7.3±16.5 to 19.6±33.9 
mg/L in the control group, and from 5.4±18.4 to 12.6±24.8 
mg/L in the statin group (p=0.009). 
Periprocedural myocardial injury
Myocardial infarction, defined as a postprocedural eleva-
tion of CK-MB >3 times the upper normal limit or baseline 
level, was detected in 16 (6.6%) of patients in the control group 
and in 5 (2.1%) patients in the statin group (p=0.016). More-
over, the incidences of a >5 fold elevation in postprocedural 
CK-MB levels (4.1% vs. 1.3%, p=0.048), and a >1 fold eleva-
tion (37.2% vs. 21.5%, p<0.001), was higher in the control gr-
oup than in the statin group (Fig. 1).
Troponin T elevation after PCI was also higher in the con-
trol group than in the statin group. The instances of overall 
elevation in troponin T levels (43.4% vs. 31.2%, p=0.006), >3 
times elevation in troponin T levels (24.0% vs. 15.2%, p=0.016), 
and >5 times elevation in troponin T levels (13.6% vs. 8.4%, 
p=0.070) after PCI occurred more frequently in the control 
group than in the statin group.
In-hospital major adverse cardiovascular events
The patients in the statin group had a lower incidence of 
in-hospital MACE compared to the patients in the control gr-
oup (8.3% vs. 3.0%, p=0.012). The different outcomes mainly 
resulted from a higher incidence of periprocedural MI in the 
control group (Table 4).
A multivariate analysis revealed that no prior use of statin 
{odds ratio (OR)=2.8; 95% confidence interval (CI)=1.1-7.2; 
p=0.038), procedural complication (OR=4.0; 95% CI=1.5-
10.5; p=0.004), stent overlap (OR=4.7; 95% CI=1.3-16.4; p= 
0.015), and old age (OR=3.2; 95% CI=1.2-8.0; p=0.016) were 
independent predictors for in-hospital MACE (Table 5).
Discussion
In this study, we showed that previous statin therapy be-
fore ACS was associated with milder clinical presentation 
and lower incidence of MACE after an early invasive strategy. 
The beneficial outcomes observed in the statin group can be 
attributed to a reduction in the inflammatory response and 
periprocedural MI after PCI.
Statin therapy before PCI has been shown to reduce the in-
cidence of periprocedural MI and improve outcomes in pa-
Table 1. Baseline clinical characteristics 
 
Control group
(n=242)
Statin group 
(n=237)
p
Age (years) 63±11 63±11 0.961
Male (%) 153 (63) 130 (55) 0.062
Hypertension (%) 136 (56) 152 (64) 0.076
Diabetes (%) 073 (30) 087 (37) 0.129
Smoker (%) 104 (43) 095 (40) 0.521
Previous PCI (%)  14 (6) 20 (8) 0.258
Clinical presentation (%)  <0.001
    Unstable angina 160 (66) 195 (82)
    NSTEMI 082 (34) 042 (18)
Braunwald class (%) <0.001
    I 096 (40) 133 (56)
    II 052 (21) 060 (25)
    III 094 (39) 044 (19)
Total cholesterol (mg/dL) 202±460 189±480 0.003
Triglyceride (mg/dL) 172±128 166±101 0.545
HDL-C (mg/dL) 45±12 44±11 0.465
LDL-C (mg/dL) 124±400 113±420 0.002
Lipoprotein (a) (mg/dL) 40±43 40±34 0.960
PCI: percutaneous coronary intervention, NSTEMI: non-ST-seg-
ment elevation myocardial infarction, HDL-C: high density lipo-
protein-cholesterol, LDL-C: low density lipoprotein-cholesterol
Table 2. Coronary angiographic and procedural characteristics
  
Control group
(n=242)
Statin group 
(n=237)
p
Multi-vessel disease (%) 132 (55) 121 (51) 0.444
Target vessel (%) 0.230
    LAD 119 (49) 119 (50)
    LCX 059 (24) 047 (20)
    RCA 052 (22) 056 (24)
    Left main 012 (5) 015 (6)
ACC/AHA B2/C lesion (%) 174 (72) 181 (76) 0.264
Calcification (%) 017 (7) 021 (9) 0.457
Bifurcation (%) 077 (32) 069 (29) 0.520
Thrombus (%) 017 (7) 013 (6) 0.487
Drug-eluting stent (%) 231 (96) 232 (98) 0.138
Stent diameter (mm) 3.2±0.4 3.2±0.4 0.178
Stent length (mm) 44±27 44±27 0.836
Stent number 1.6±0.9 1.7±0.9 0.501
Maximal pressure (atm) 17±40 17±30 0.374
Multi-vessel stenting (%) 073 (30) 073 (31) 0.880
Stent overlap (%) 036 (15) 047 (20) 0.152
2 stenting in bifurcation (%) 007 (3) 011 (5) 0.346
Use of GPI (%) 025 (10) 031 (13) 0.424
Complications (%)
    Slow/No reflow 018 (7) 006 (3) 0.014
    Distal embolization 002 (0.8) 001 (0.4) 1.000
    Side-branch occlusion 008 (3) 009 (4) 0.771
    Dissection >type C 008 (3) 001 (0.4) 0.037
LAD: left anterior descending artery, LCX: left circumflex artery, 
RCA: right coronary artery, ACC/AHA: American College of Car-
diology/American Heart Association lesion classification, GPI: gly-
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tients with stable angina. Briguori et al.
14) reported that the 
incidence of CK-MB elevation greater than five times the 
upper normal limit after PCI was approximately 50% lower 
in statin-treated angina patients as compared to the statin-
naïve patients. In addition, the CK-MB peak after stenting 
was shown to be significantly lower in the statin group than 
in the control group. Another study demonstrated that ch-
ronic statin therapy before PCI reduced CK-MB by greater 
than three times the elevation after PCI and decreased the 
incidence of 6-12 months MACE.
12)15) Further, a meta-anal-
ysis showed that statin pretreatment in patients with stable 
angina resulted in a 59.3% reduction of relative risk of pro-
cedural MI and a 20.5% overall reduction in MACE.
16) How-
ever, there was a limitation on data regarding the clinical be-
nefits of chronic pretreatment with statins in patients with 
ACS undergoing PCI.
Previous studies have also shown that statin therapy im-
proves the prognosis of patients with ACS. The Pravastatin or 
Atorvastatin Evaluation and Infection Therapy study report-
ed that intensive statin therapy within 10 days after ACS re-
sults in 28% and 6% risk reduction at 30 days and two years, 
respectively.
8) Further, the Myocardial Ischemia Reduction 
with Aggressive Cholesterol Lowering study reported that 80 
mg atorvastatin within 24-96 hours after hospital admission 
reduced the risk of the composite primary end point of death, 
MI, cardiac arrest, and recurrent ischemia by 16% compared 
Table 4. In-hospital major adverse cardiovascular events in con-
trol and statin-treated groups
 
Control group
(n=242)
Statin group 
(n=237)
p
Death 03 (1.2) 1 (0.4) 0.624
Non-periprocedural QMI 00 (0) 2 (0.8) 0.244
Periprocedural MI 16 (6.6) 5 (2.1) 0.016
Revascularization 00 (0) 0 (0) -
Ischemic stroke 01 (0.4) 1 (0.4) 1.000
Total 20 (8.3) 7 (3.0)* 0.012
*Two patients with periprocedural myocardial infarction experi-
enced re-infarction on a subsequent hospital day. QMI: Q wave 
myocardial infarction, MI: myocardial infarction
Table 5. Multivariate analysis for the prediction of in-hospital ma-
jor adverse cardiovascular events
OR 95% CI p
Procedural complication 4.0 1.5-10.5 0.004
Stent overlap 4.7 1.3-16.4 0.015
Age >65 years 3.2 1.2-8.00 0.016
No use of statin 2.8 1.1-7.20 0.038
NSTEMI 2.0 0.8-5.00 0.139
Thrombus lesion 2.4 0.6-9.10 0.210
Use of GPI 0.9 0.2-3.00 0.806
OR: odds ratio, CI: confidence interval, NSTEMI: non-ST-segment 
elevation myocardial infarction, GPI: glycoprotein IIb/IIIa inhibitor
Table 3. Changes of inflammatory and myocardial biomarker after percutaneous coronary intervention
Variables
Control group (n=242) Statin group (n=237) p
(Baseline)
p 
(24 hours)
p 
(Changes) Baseline 24 hours Changes Baseline 24 hours Changes
White blood cell (/µL) 8,165±2,763 8,376±2,515 206±2,302 7,751±2,260 8,072±2,073 322±1,929 0.073 0.151 0.550
hsCRP (mg/L) 07.3±16.5 19.6±33.9 12.9±29.90. 05.4±18.4 12.6±24.8 7.0±15.9 0.250 0.011 0.009
Fibrinogen (mg/dL) 305±950 338±930 33±780. 279±820 296±860 17±900 0.002 <0.001 0.042
CKMB (IU/L) 31±37 38±37 6±39. 26±36 28±25 2±33 0.092 0.001 0.217
Troponin T (ng/mL) 0.4±1.0 0.7±1.4 0.4±1.00. 0.2±0.6 0.4±0.9 0.2±0.80 0.024 0.003 0.052
hsCRP: high sensitivity C-reactive protein, CK-MB: creatine kinase MB
Fig. 1. Incidence of cardiac biomarker elevation after percutaneous coronary intervention. A: incidences of any CK-MB elevation (37.2% vs. 
21.5%, p<0.001), >3 times elevation (6.6% vs. 2.1%, p=0.016), and >5 times elevation (4.1% vs. 1.3%, p=0.054) were higher in the control 
group than in the statin group. B: incidences of any troponin elevation (43.4% vs. 31.2%, p=0.006), >3 times elevation (24.0% vs. 15.2%, 
p=0.016), and >5 times elevation (13.6% vs. 8.4%, p=0.070) were higher in the control group than in the statin group.
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to placebo.
7) In addition, we previously reported that high 
dose statin loading approximately 16 hours before PCI re-
sulted in a 53% reduction in the risk of periprocedural MI and 
a 63% reduction in the risk of 30-day MACE, compared to no 
statin pretreatment.
10) These studies indicate that early statin 
therapy significantly improves the prognosis of patients with 
ACS. In the current study, we demonstrated that previous st-
atin therapy prior to the onset of ACS also has beneficial ef-
fects on the reduction of periprocedural MI and improvement 
of the in-hospital clinical course after PCI.
Previous statin therapy seems to attenuate the severity and 
extent of MI. In an analysis of the Global Registry of Acute 
Coronary Events registry, patients receiving statins had a lo-
wer incidence of MI and cardiogenic shock. Size of infarcted 
myocardium was significantly smaller because ST-segment 
elevation MI occurred less often, and CK levels were lower 
among patients with chronic statin therapy.
17) Previous statin 
therapy also has been demonstrated to favorably affect the 
hospital outcome in patients with MI. Bauer et al.
18) reported 
that pretreatment with statins was associated with smaller 
MI size and a 35% reduction of hospital mortality in patients 
with non-ST-segment elevation MI. The results of the current 
study were similar to those of the aforementioned studies, de-
spite differences in the study population. Overall, patients with 
previous statin therapy revealed lower levels of baseline and 
peak troponin and a lower incidence of in-hospital MACE.
The benefits of statins in cardiovascular diseases can be 
explained not only by their lipid-lowering potential but also 
by mechanisms unrelated to lipids, or the so called pleiotropic 
effects.
19) Such pleiotropic effects encompass non-lipid mech-
anisms that modify endothelial function, inflammatory re-
sponses, plaque stability, and thrombus formation.
20) Thus, 
they may potentially improve outcomes after PCI. Our study 
showed a lower elevation of hsCRP levels after PCI in patients 
undergoing previous statin therapy. Previous studies have sh-
own that elevation of hsCRP levels after PCI to be associated 
with troponin elevation, and periprocedural myocardial in-
jury has been shown to be correlated with vascular inflam-
mation.
21)22) Moreover, the CRP elevation after PCI has been 
associated with a higher incidence of MACE in patients with 
ACS.
23) In the current study, the hsCRP peak after stenting was 
significantly lower in the statin group than in the control gr-
oup, supporting the notion that prevention of myocardial in-
jury via lipid lowering and pleiotrophic effects of statins is im-
portant in improving the clinical outcomes in patients with 
ACS.
Our study has several limitations. The study was not ran-
domized, and the sample size was small. It was difficult to ran-
domize because the study group was classified by long-term 
treatment status. Furthermore, the clinical outcomes accord-
ing to the type and dose of statins and the exact duration of 
the therapy were not identified due to the small sample size. 
A large registry study is needed to generalize our results. 
 In conclusion, previous statin therapy before PCI attenu-
ated the clinical presentation of ACS and was associated with 
a lower incidence of MACE after an early invasive strategy. 
Inflammatory responses after PCI were also inhibited by a 
reduction of myocardial injury during the intervention in 
patients who had previously received statin therapy.
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